Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
Total Valuation
Ultragenyx Pharmaceutical has a market cap or net worth of $2.73B. The enterprise value is $3.97B.
Market Cap$2.73B
Enterprise Value$3.97B
Share Statistics
Ultragenyx Pharmaceutical has 94,542,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding94,542,040
Owned by Insiders4.09%
Owned by Institutions1.30%
Financial Efficiency
Ultragenyx Pharmaceutical’s return on equity (ROE) is -2.23 and return on invested capital (ROIC) is -45.55%.
Return on Equity (ROE)-2.23
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-45.55%
Return on Capital Employed (ROCE)-0.46
Revenue Per Employee432.94K
Profits Per Employee-439.86K
Employee Count1,294
Asset Turnover0.37
Inventory Turnover1.70
Valuation Ratios
The current PE Ratio of Ultragenyx Pharmaceutical is ―. Ultragenyx Pharmaceutical’s PEG ratio is 0.28.
PE Ratio―
PS Ratio6.80
PB Ratio14.92
Price to Fair Value14.92
Price to FCF-9.03
Price to Operating Cash Flow-6.78
PEG Ratio0.28
Income Statement
In the last 12 months, Ultragenyx Pharmaceutical had revenue of 560.23M and earned -569.18M in profits. Earnings per share was -6.29.
Revenue560.23M
Gross Profit483.50M
Operating Income-535.97M
Pretax Income-567.59M
Net Income-569.18M
EBITDA-469.00M
Earnings Per Share (EPS)-6.29
Cash Flow
In the last 12 months, operating cash flow was -421.25M and capital expenditures -6.05M, giving a free cash flow of -427.30M billion.
Operating Cash Flow-421.25M
Free Cash Flow-427.30M
Free Cash Flow per Share-4.52
Dividends & Yields
Ultragenyx Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.24
52-Week Price Change-44.66%
50-Day Moving Average33.32
200-Day Moving Average40.06
Relative Strength Index (RSI)38.77
Average Volume (3m)2.58M
Important Dates
Ultragenyx Pharmaceutical upcoming earnings date is Nov 4, 2025, TBA (Confirmed).
Last Earnings DateAug 5, 2025
Next Earnings DateNov 4, 2025
Ex-Dividend Date―
Financial Position
Ultragenyx Pharmaceutical as a current ratio of 2.37, with Debt / Equity ratio of 26.53%
Current Ratio2.37
Quick Ratio2.24
Debt to Market Cap<0.01
Net Debt to EBITDA-1.57
Interest Coverage Ratio-8.50
Taxes
In the past 12 months, Ultragenyx Pharmaceutical has paid 1.60M in taxes.
Income Tax1.60M
Effective Tax Rate>-0.01
Enterprise Valuation
Ultragenyx Pharmaceutical EV to EBITDA ratio is -9.69, with an EV/FCF ratio of -10.78.
EV to Sales8.11
EV to EBITDA-9.69
EV to Free Cash Flow-10.78
EV to Operating Cash Flow-10.97
Balance Sheet
Ultragenyx Pharmaceutical has $487.58M in cash and marketable securities with $11.77M in debt, giving a net cash position of -$475.82M billion.
Cash & Marketable Securities$487.58M
Total Debt$11.77M
Net Cash-$475.82M
Net Cash Per Share-$5.03
Tangible Book Value Per Share$0.44
Margins
Gross margin is 83.63%, with operating margin of -95.67%, and net profit margin of -101.60%.
Gross Margin83.63%
Operating Margin-95.67%
Pretax Margin-101.31%
Net Profit Margin-101.60%
EBITDA Margin-83.72%
EBIT Margin-90.06%
Analyst Forecast
The average price target for Ultragenyx Pharmaceutical is $83.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$83.43
Price Target Upside199.78% Upside
Analyst ConsensusStrong Buy
Analyst Count16
Revenue Growth Forecast26.77%
EPS Growth Forecast24.18%